Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 10/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 3/20 | 0.34 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2410553 | 1.00 | GSR (0.39) | GSRCA2ALDH1A1BCHEFFAR3 | |
| SCHEMBL637049 | 0.93 | GSR (0.44) | GSRCA2ALDH1A1BCHEFFAR3 | |
| SCHEMBL16242306 | 0.88 | GSR (0.39) | GSRCA2ALDH1A1BCHEFFAR3 | |
| SCHEMBL16242346 | 0.88 | GSR (0.39) | GSRCA2ALDH1A1BCHEFFAR3 | |
| SCHEMBL16242333 | 0.88 | GSR (0.39) | GSRCA2ALDH1A1BCHEFFAR3 | |
| SCHEMBL16242338 | 0.88 | GSR (0.39) | GSRCA2ALDH1A1BCHEFFAR3 | |
| SCHEMBL16242285 | 0.88 | GSR (0.39) | GSRCA2ALDH1A1BCHEFFAR3 | |
| SCHEMBL16242400 | 0.88 | GSR (0.39) | GSRCA2ALDH1A1BCHEFFAR3 | |
| SCHEMBL16242390 | 0.88 | GSR (0.39) | GSRCA2ALDH1A1BCHEFFAR3 | |
| SCHEMBL2410373 | 0.82 | GSR (0.38) | GSRCA2ALDH1A1BCHEFFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119806-B2 | Cicletanine derivatives | MERCK SHARP & DOHME CORP. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110230532-A1 | NITROOXY CYCLOALKANE DERIVATIVES | MERCK SHARP & DOHME LLC | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230532-A1 | NITROOXY CYCLOALKANE DERIVATIVES | AGTR2, AGTR1, NR3C2 | GSR 761/4885CA2 213/4885ALDH1A1 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.